Kyowa Kirin Yönetim

Yönetim kriter kontrolleri 4/4

Kyowa Kirin CEO'su Masashi Miyamoto, Mar2018 tarihinde atandı, in görev süresi 6.67 yıldır. in toplam yıllık tazminatı ¥ 157.00M olup, şirket hissesi ve opsiyonları dahil olmak üzere 52.9% maaş ve 47.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.018% ine doğrudan sahiptir ve bu hisseler ¥ 243.05M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 3.2 yıldır.

Anahtar bilgiler

Masashi Miyamoto

İcra Kurulu Başkanı

JP¥157.0m

Toplam tazminat

CEO maaş yüzdesi	52.9%
CEO görev süresi	6.7yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	3.2yrs

Son yönetim güncellemeleri

Recent updates

What Kyowa Kirin Co., Ltd.'s (TSE:4151) P/E Is Not Telling You

Oct 22

Kyowa Kirin Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 03

Earnings Miss: Kyowa Kirin Co., Ltd. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

May 09

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Apr 25

Kyowa Kirin's (TSE:4151) Dividend Will Be ¥29.00

Apr 11

Here's Why We Think Kyowa Kirin (TSE:4151) Is Well Worth Watching

Mar 19

Kyowa Kirin Co., Ltd.'s (TSE:4151) 26% Price Boost Is Out Of Tune With Earnings

Feb 27

CEO Tazminat Analizi

Masashi Miyamoto'un ücretlendirmesi Kyowa Kirin'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	JP¥84b
Jun 30 2024	n/a	n/a	JP¥97b
Mar 31 2024	n/a	n/a	JP¥83b
Dec 31 2023	JP¥157m	JP¥83m	JP¥81b
Sep 30 2023	n/a	n/a	JP¥58b
Jun 30 2023	n/a	n/a	JP¥40b
Mar 31 2023	n/a	n/a	JP¥50b
Dec 31 2022	JP¥182m	JP¥83m	JP¥54b

Tazminat ve Piyasa: Masashi 'ın toplam tazminatı ($USD 1.03M ) JP pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 1.08M ).

Tazminat ve Kazançlar: Masashi 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Masashi Miyamoto (65 yo)

6.7yrs

Görev süresi

JP¥157,000,000

Tazminat

Mr. Masashi Miyamoto Ph D., serves as Representative Director at Kyowa Kirin Co., Ltd. He serves as President of Kyowa Hakko Kirin Co., Ltd since March 2018, served as a Chief Operating Officer since March...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Masashi Miyamoto	President	6.7yrs	JP¥157.00m	0.018% ¥ 243.0m
Motohiko Kawaguchi	CFO & Managing Executive Officer	no data	Veri yok	Veri yok
Yutaka Osawa	CCO, Executive VP & Representative Director	2.8yrs	JP¥105.00m	0.013% ¥ 170.0m
Kazuki Nemoto	Head of Global Legal	1.6yrs	Veri yok	Veri yok
Hiroki Nakamura	Global Corporate Communications Head	no data	Veri yok	Veri yok
Hiroshi Sonekawa	Managing Executive Officer	3.7yrs	Veri yok	Veri yok
Shoko Itagaki	Executive Officer & Chief People Officer	less than a year	Veri yok	Veri yok
Takeyoshi Yamashita	Chief Medical Officer	3.8yrs	Veri yok	0.0052% ¥ 68.8m
Yasuo Fujii	Chief Strategy Officer	6.8yrs	Veri yok	Veri yok
Jean-David Rafizadeh-Kabe	Head of Global Operational Transformation	2.8yrs	Veri yok	Veri yok
Yoshifumi Torii	Executive Officer & Head of Global Research	no data	Veri yok	Veri yok
Hiroki Takamatsu	VP, Head of Quality Assurance Division & Executive Officer	no data	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim: 4151 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Masashi Miyamoto	President	13.6yrs	JP¥157.00m	0.018% ¥ 243.0m
Yutaka Osawa	CCO, Executive VP & Representative Director	6.7yrs	JP¥105.00m	0.013% ¥ 170.0m
Takeyoshi Yamashita	Chief Medical Officer	1.7yrs	Veri yok	0.0052% ¥ 68.8m
Yoshihisa Q. Suzuki	Independent Outside Director	2.7yrs	Veri yok	0.00025% ¥ 3.3m
Hiroshi Komatsu	Full-time Audit & Supervisory Board Member	6.7yrs	Veri yok	0.00086% ¥ 11.3m
Akira Morita	Outside Independent Chairman	5.7yrs	Veri yok	0.00067% ¥ 8.8m
Yuko Haga	Independent Outside Director	5.7yrs	Veri yok	0.00086% ¥ 11.3m
Mayumi Tamura	Outside Audit & Supervisory Board Member	2.7yrs	Veri yok	0.00011% ¥ 1.4m
Takashi Oyamada	Independent Outside Director	3.7yrs	Veri yok	0.00059% ¥ 7.8m
Shinjiro Akieda	Director	less than a year	Veri yok	Veri yok
Rumiko Nakata	Independent Outside Director	1.7yrs	Veri yok	0.000040% ¥ 527.2k
Toru Ishikura	Audit & Supervisory Board Member	1.7yrs	Veri yok	Veri yok

3.2yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4151 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.2 yıldır).

Kyowa Kirin Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Kyowa Kirin Co., Ltd. Announces Yutaka Osawa, Executive Vice President and Chief Compliance Officer, Effective March 2025

Kyowa Kirin Co., Ltd. Announces Yutaka Osawa, Executive Vice President and Chief Compliance Officer, Effective March 2025

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 22, 2024

High number of new directors

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 24, 2023

High number of new directors

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Kyowa Kirin Co., Ltd. Announces Yutaka Osawa, Executive Vice President and Chief Compliance Officer, Effective March 2025

Kyowa Kirin Co., Ltd. Announces Yutaka Osawa, Executive Vice President and Chief Compliance Officer, Effective March 2025

What Kyowa Kirin Co., Ltd.'s (TSE:4151) P/E Is Not Telling You

Investor sentiment deteriorates as stock falls 17%

Kyowa Kirin Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Kyowa Kirin Co., Ltd. Updates Earnings Guidance for He Fiscal Year 2024

Here's Why Kyowa Kirin (TSE:4151) Has Caught The Eye Of Investors

Kyowa Kirin Co., Ltd.'s (TSE:4151) Share Price Could Signal Some Risk

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Are Investors Undervaluing Kyowa Kirin Co., Ltd. (TSE:4151) By 35%?

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2024 Results on Feb 06, 2025

Earnings Miss: Kyowa Kirin Co., Ltd. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

First quarter 2024 earnings: EPS misses analyst expectations

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Kyowa Kirin's (TSE:4151) Dividend Will Be ¥29.00

Final dividend of JP¥29.00 announced

Here's Why We Think Kyowa Kirin (TSE:4151) Is Well Worth Watching

Kyowa Kirin Co., Ltd. to Present Phase 2B Post-Hoc Analysis and Symposium At the American Academy of Dermatology Annual Meeting 2024

Kyowa Kirin Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Kyowa Kirin Co., Ltd.'s (TSE:4151) 26% Price Boost Is Out Of Tune With Earnings

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

Kyowa Kirin Co., Ltd. Declares Dividend for the Fiscal Year Ended December 31, 2023, Payable on March 25, 2024; Provides Dividend Guidance for the Second Quarter of 2024

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 22, 2024

Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2023 Results on Feb 07, 2024

Upcoming dividend of JP¥27.00 per share at 2.3% yield

Now 20% undervalued after recent price drop

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Kyowa Kirin Co., Ltd. (TSE:4151) entered into a Transaction Agreement to acquire Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others for approximately $470 million.

Kyowa Kirin Co., Ltd. to Report Q3, 2023 Results on Nov 01, 2023

New minor risk - Earnings quality

New minor risk - Profit margin trend

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

Upcoming dividend of JP¥27.00 per share at 2.0% yield

Kyowa Kirin Co., Ltd. to Report Q1, 2024 Results on Aug 03, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Year Ending December 31, 2023

High number of new directors

Full year 2022 earnings: EPS misses analyst expectations

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 24, 2023

Kyowa Kirin Co., Ltd. Declares Dividend for the Fiscal Year Ended December 31, 2022, Payable on March 27, 2023; Provides Dividend Guidance for the Second Quarter of 2023

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2022 Results on Feb 07, 2023

Upcoming dividend of JP¥24.00 per share

Consensus forecasts updated

Kyowa Kirin Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended December 31, 2022

Kyowa Kirin Co., Ltd. and MEI Pharma, Inc. Announce Topline Data from Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-Cell Non-Hodgkin’s Lymphoma in Japan

High number of new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending December 31, 2022

Kyowa Kirin Co., Ltd. Receives European Commission Approval for Use of CRYSVITA(R) (burosumab) for the Treatment of Tumour-Induced Osteomalacia

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Kyowa Kirin Co., Ltd. Announces Second Quarter End Dividend for the Fiscal Year Ending December 31, 2022, Payable from September 1, 2022; Provided Year End Dividend Guidance for the Fiscal Year Ending December 31, 2022

MEI Pharma and Kyowa Kirin Announce Publication in the Lancet Oncology of Data from Phase 1B Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-Cell Malignancy

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)

Upcoming dividend of JP¥24.00 per share

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year Ending December 31, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new directors

High number of new directors